HK1184055A1 - Use of botulinum toxin for treating hyperhydrosis - Google Patents
Use of botulinum toxin for treating hyperhydrosisInfo
- Publication number
- HK1184055A1 HK1184055A1 HK13111511.2A HK13111511A HK1184055A1 HK 1184055 A1 HK1184055 A1 HK 1184055A1 HK 13111511 A HK13111511 A HK 13111511A HK 1184055 A1 HK1184055 A1 HK 1184055A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- botulinum toxin
- treating hyperhydrosis
- hyperhydrosis
- treating
- botulinum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89005207P | 2007-02-15 | 2007-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1184055A1 true HK1184055A1 (en) | 2014-01-17 |
Family
ID=39689504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13111511.2A HK1184055A1 (en) | 2007-02-15 | 2013-10-11 | Use of botulinum toxin for treating hyperhydrosis |
Country Status (7)
Country | Link |
---|---|
US (4) | US8388952B2 (ja) |
EP (2) | EP2583687B1 (ja) |
JP (1) | JP2010519211A (ja) |
CA (1) | CA2678038C (ja) |
ES (2) | ES2441961T3 (ja) |
HK (1) | HK1184055A1 (ja) |
WO (1) | WO2008101098A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096164A1 (en) | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
EP2583687B1 (en) * | 2007-02-15 | 2014-08-27 | Allergan, Inc. | Use of botulinum toxin for treating hyperhydrosis |
US8273721B2 (en) * | 2008-03-05 | 2012-09-25 | Endo Pharmaceuticals Solutions Inc. | Combination treatment for bladder cancer |
ES2724588T3 (es) | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
RS56460B1 (sr) * | 2011-01-07 | 2018-01-31 | Revance Therapeutics Inc | Topikalna supstanca koja sadrži botulinski toksin i boju |
JP2014510045A (ja) * | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
US9764009B2 (en) * | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
EP2731590B1 (en) * | 2011-07-13 | 2018-05-23 | The Foundry, LLC | Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets |
JP6092205B2 (ja) | 2011-07-14 | 2017-03-08 | アラーガン、インコーポレイテッドAllergan,Incorporated | 性的行為に関連した失禁の治療方法 |
US10307467B2 (en) | 2014-07-16 | 2019-06-04 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
WO2016102068A1 (en) | 2014-12-23 | 2016-06-30 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
CN107206175B (zh) | 2015-02-03 | 2021-06-01 | 莫茨制药有限及两合公司 | 肉毒杆菌毒素预填充式容器 |
RU2605624C1 (ru) * | 2015-11-23 | 2016-12-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Способ лечения детрузорной гиперактивности |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69019141T2 (de) | 1989-01-27 | 1996-01-18 | Immunolytics Inc | Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ES2238969T3 (es) | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
EP0809509A4 (en) * | 1995-01-13 | 2000-02-02 | Salk Inst For Biological Studi | ALLOSTERIC REGULATION OF NUCLEAR HORMONE RECEPTORS |
US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
FR2763958A1 (fr) * | 1997-05-29 | 1998-12-04 | Transgene Sa | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
US7470431B2 (en) * | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
ES2385130T3 (es) * | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6428785B1 (en) * | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US20030212021A1 (en) | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
CA2460042C (en) | 2000-09-26 | 2012-05-08 | Sidney Kimmel Cancer Center | Inhibition of antigen presentation with poorly catabolized polymers |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
BR0006556A (pt) * | 2000-12-28 | 2002-09-17 | Apsen Farmaceutica S A | Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US20040067235A1 (en) | 2002-07-29 | 2004-04-08 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
WO2004058147A2 (en) | 2002-12-16 | 2004-07-15 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2004110360A2 (en) * | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
EP2248534A1 (en) * | 2005-06-14 | 2010-11-10 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
KR101235135B1 (ko) * | 2005-12-19 | 2013-02-20 | 삼성디스플레이 주식회사 | 금속 배선, 이의 제조 방법, 이를 구비한 표시 기판 및표시 기판의 제조 방법 |
WO2008030638A2 (en) | 2006-05-16 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
EP2583687B1 (en) | 2007-02-15 | 2014-08-27 | Allergan, Inc. | Use of botulinum toxin for treating hyperhydrosis |
-
2008
- 2008-02-14 EP EP13151292.3A patent/EP2583687B1/en not_active Not-in-force
- 2008-02-14 ES ES08743476.7T patent/ES2441961T3/es active Active
- 2008-02-14 WO PCT/US2008/053989 patent/WO2008101098A2/en active Application Filing
- 2008-02-14 EP EP08743476.7A patent/EP2117584B1/en not_active Not-in-force
- 2008-02-14 JP JP2009549723A patent/JP2010519211A/ja active Pending
- 2008-02-14 ES ES13151292.3T patent/ES2520765T3/es active Active
- 2008-02-14 CA CA2678038A patent/CA2678038C/en not_active Expired - Fee Related
- 2008-02-15 US US12/032,013 patent/US8388952B2/en active Active
- 2008-02-15 US US12/032,057 patent/US8383103B2/en active Active
-
2013
- 2013-01-31 US US13/755,282 patent/US8697066B2/en active Active
- 2013-01-31 US US13/755,310 patent/US20130142770A1/en not_active Abandoned
- 2013-10-11 HK HK13111511.2A patent/HK1184055A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2583687B1 (en) | 2014-08-27 |
US20130142770A1 (en) | 2013-06-06 |
US20130129699A1 (en) | 2013-05-23 |
CA2678038C (en) | 2016-10-11 |
US20080199452A1 (en) | 2008-08-21 |
US8697066B2 (en) | 2014-04-15 |
EP2117584B1 (en) | 2013-10-09 |
US8388952B2 (en) | 2013-03-05 |
ES2520765T3 (es) | 2014-11-11 |
WO2008101098A2 (en) | 2008-08-21 |
EP2583687A1 (en) | 2013-04-24 |
US8383103B2 (en) | 2013-02-26 |
EP2117584A2 (en) | 2009-11-18 |
ES2441961T3 (es) | 2014-02-07 |
CA2678038A1 (en) | 2008-08-21 |
US20080199453A1 (en) | 2008-08-21 |
JP2010519211A (ja) | 2010-06-03 |
WO2008101098A3 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1184055A1 (en) | Use of botulinum toxin for treating hyperhydrosis | |
IL195201A0 (en) | High frequency application of botulinum toxin therapy | |
EP2300005A4 (en) | Small-molecule inhibitors of botulinum neurotoxins | |
IL244154A0 (en) | Botulinum neurotoxin for use in the treatment of depression | |
EP2337778A4 (en) | METHODS OF TREATING BOTULINUM TOXIN-RELATED DISEASE IN A SUBJECT | |
IL205280A0 (en) | Methods of treating chronic neurogenic inflammation using modified clostridial toxins | |
EP2338519A4 (en) | MEANS FOR THE TREATMENT OF MYELOFIBROSIS | |
PT2310034E (pt) | Péptidos para o tratamento de beta-amiloidoses | |
IL199907A0 (en) | Composition for treatment of pancreatic cancer | |
EP2490530A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
EP2419128A4 (en) | MANIPULATED BOTULINUM NEUROTOXIN | |
EP2308493A4 (en) | ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA | |
IL193639A0 (en) | Collagenase for treating cellulite | |
IL207292A0 (en) | Use of ranolazine for treating pain | |
EP2313434A4 (en) | NEUTRALIZING ANTIBODIES OF BOTULINIC NEUROTOXINS | |
IL214665A (en) | Alkyl-amido compounds and their uses in the treatment of acne | |
HK1163524A1 (zh) | 胰腺腫瘤治療 | |
EP2078522A4 (en) | COMPOSITION FOR THE TREATMENT OF ALLERGIES | |
EP2341936A4 (en) | METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES | |
WO2011009097A9 (en) | Methods for treating schizophrenia | |
EP2368559A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF ATHEROSCLEROSIS | |
EP2397460A4 (en) | NITROGEN-CONTAINING COMPOUNDS AND AGENTS FOR CONTROLLING HARMFUL ORGANISMS | |
HK1174532A1 (en) | Compositions comprising botulinum toxin a or b for use in the treatment of osteoporosis a b | |
ZA200807221B (en) | Collagenase for treating cellulite | |
EP2510931A4 (en) | THERAPEUTIC AGENT FOR THE PREVENTION AND TREATMENT OF ADENOMA AND PROSTATITIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220217 |